To embed, copy and paste the code into your website or blog: On 17 May 2021, the Acting Administrator of the Health Resources and Services Administration (HRSA), Diana Espinosa, sent letters to six pharmaceutical manufacturers stating that the manufacturers’ actions to limit access to 340B Program pricing for covered entities that dispense medications through contract pharmacies have resulted in overcharges and are in direct violation of the 340B statute. 1 The letters order the manufacturers to immediately begin offering 340B pricing to covered entities through their contract pharmacy arra...